Quick Answer AbCellera Biologics Inc. reported Shares Outstanding of 300.60 million shares for fiscal year 2025. AbCellera Biologics Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 300.60M +1.6% 2024 295.76M +1.7% 2023 290.82M +1.4% 2022 286.85M +1.3% 2021 283.26M +5.1% 2020 269.50M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding … Read more
Quick Answer AbCellera Biologics Inc. reported Operating Income of -$217.10 million for fiscal year 2025. AbCellera Biologics Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$217.10M +31.0% 2024 -$314.77M -32.7% 2023 -$237.21M -209.6% 2022 $216.51M +5.9% 2021 $204.41M +31.0% 2020 $156.03M +3889.9% 2019 -$4.12M — Quarterly Operating Income Quarter Ending … Read more
Quick Answer AbCellera Biologics Inc. reported R&D Expense of $186.83 million for fiscal year 2025. AbCellera Biologics Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $186.83M +11.7% 2024 $167.26M -4.8% 2023 $175.66M +62.8% 2022 $107.88M +73.8% 2021 $62.06M +111.1% 2020 $29.39M +190.6% 2019 $10.11M — Quarterly R&D Expense Quarter Ending … Read more
Quick Answer AbCellera Biologics Inc. reported Stockholders Equity of $966.90 million for fiscal year 2025. AbCellera Biologics Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $966.90M -8.4% 2024 $1.06B -8.4% 2023 $1.15B -6.6% 2022 $1.23B +20.2% 2021 $1.03B +23.5% 2020 $830.51M +8000.9% 2019 $10.25M -11.7% 2018 $11.61M — Quarterly Stockholders … Read more
Quick Answer AbCellera Biologics Inc. reported Cash and Equivalents of $61.80 million for fiscal year 2025. AbCellera Biologics Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $61.80M +11.2% 2024 $55.60M -58.3% 2023 $133.32M +196.9% 2022 $44.90M +447.6% 2021 $8.20M -98.6% 2020 $594.12M — Quarterly Cash and Equivalents Quarter … Read more
Quick Answer AbCellera Biologics Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025. AbCellera Biologics Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$0.49 +10.9% 2024 -$0.55 -7.8% 2023 -$0.51 -202.0% 2022 $0.50 +4.2% 2021 $0.48 +6.7% 2020 $0.45 +4600.0% 2019 -$0.01 — Quarterly Diluted EPS … Read more
Quick Answer AbCellera Biologics Inc. reported Total Assets of $1.36 billion for fiscal year 2025. AbCellera Biologics Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $1.36B -0.3% 2024 $1.36B -8.6% 2023 $1.49B -3.4% 2022 $1.54B +16.9% 2021 $1.32B +31.1% 2020 $1.01B — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer AbCellera Biologics Inc. reported Net Income of -$146.41 million for fiscal year 2025. AbCellera Biologics Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$146.41M +10.1% 2024 -$162.86M -11.2% 2023 -$146.40M -192.4% 2022 $158.52M +3.3% 2021 $153.46M +29.1% 2020 $118.92M +5478.5% 2019 -$2.21M — Quarterly Net Income Quarter Ending … Read more
Quick Answer AbCellera Biologics Inc. reported Revenue (ASC 606) of $75.13 million for fiscal year 2025. AbCellera Biologics Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $75.13M +160.6% 2024 $28.83M -24.2% 2023 $38.02M -92.2% 2022 $485.42M +29.4% 2021 $375.20M +60.9% 2020 $233.16M +1907.9% 2019 $11.61M — Quarterly Revenue … Read more
Quick Answer AbCellera Biologics Inc. reported Total Revenue of $75.13 million for fiscal year 2025. AbCellera Biologics Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $75.13M+160.6% $28.83M-24.2% $38.02M-92.2% $485.42M+29.4% $375.20M+60.9% $233.16M+1907.9% Revenue (ASC 606) $75.13M+160.6% $28.83M-24.2% $38.02M-92.2% $485.42M+29.4% $375.20M+60.9% $233.16M+1907.9% Net Income -$146.41M+10.1% -$162.86M-11.2% -$146.40M-192.4% $158.52M+3.3% $153.46M+29.1% $118.92M+5478.5% … Read more